Cargando…

Genome-wide identification of inter-individually variable DNA methylation sites improves the efficacy of epigenetic association studies

Epigenome-wide association studies, which searches for blood-based DNA methylation signatures associated with environmental exposures and/or disease susceptibilities, is a promising approach to a better understanding of the molecular aetiology of common diseases. To carry out large-scale epigenome-w...

Descripción completa

Detalles Bibliográficos
Autores principales: Hachiya, Tsuyoshi, Furukawa, Ryohei, Shiwa, Yuh, Ohmomo, Hideki, Ono, Kanako, Katsuoka, Fumiki, Nagasaki, Masao, Yasuda, Jun, Fuse, Nobuo, Kinoshita, Kengo, Yamamoto, Masayuki, Tanno, Kozo, Satoh, Mamoru, Endo, Ryujin, Sasaki, Makoto, Sakata, Kiyomi, Kobayashi, Seiichiro, Ogasawara, Kuniaki, Hitomi, Jiro, Sobue, Kenji, Shimizu, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5677974/
https://www.ncbi.nlm.nih.gov/pubmed/29263827
http://dx.doi.org/10.1038/s41525-017-0016-5
Descripción
Sumario:Epigenome-wide association studies, which searches for blood-based DNA methylation signatures associated with environmental exposures and/or disease susceptibilities, is a promising approach to a better understanding of the molecular aetiology of common diseases. To carry out large-scale epigenome-wide association studies while avoiding false negative detection, an efficient strategy to determine target CpG sites for microarray-based or sequencing-based DNA methylation profiling is essentially needed. Here, we propose and validate a hypothesis that a strategy focusing on CpG sites with high DNA methylation level variability may attain an improved efficacy. Through whole-genome bisulfite sequencing of purified blood cells collected from > 100 apparently healthy subjects, we identified ~2.0 million inter-individually variable CpG sites as potential targets. The efficacy of our strategy was estimated to be 3.7-fold higher than that of the most frequently used strategy. Our catalogue of inter-individually variable CpG sites will accelerate the discovery of clinically relevant DNA methylation biomarkers in future epigenome-wide association studies.